key: cord-0692617-vajp7onx
authors: Engelen, Suzanne E.; Robinson, Alice J. B.; Zurke, Yasemin-Xiomara; Monaco, Claudia
title: Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
date: 2022-01-31
journal: Nat Rev Cardiol
DOI: 10.1038/s41569-021-00668-4
sha: ce73f8924a37d5c81f0cdcf0044ee43033500397
doc_id: 692617
cord_uid: vajp7onx

Atherosclerosis is a chronic inflammatory disease of the arterial wall, characterized by the formation of plaques containing lipid, connective tissue and immune cells in the intima of large and medium-sized arteries. Over the past three decades, a substantial reduction in cardiovascular mortality has been achieved largely through LDL-cholesterol-lowering regimes and therapies targeting other traditional risk factors for cardiovascular disease, such as hypertension, smoking, diabetes mellitus and obesity. However, the overall benefits of targeting these risk factors have stagnated, and a huge global burden of cardiovascular disease remains. The indispensable role of immunological components in the establishment and chronicity of atherosclerosis has come to the forefront as a clinical target, with proof-of-principle studies demonstrating the benefit and challenges of targeting inflammation and the immune system in cardiovascular disease. In this Review, we provide an overview of the role of the immune system in atherosclerosis by discussing findings from preclinical research and clinical trials. We also identify important challenges that need to be addressed to advance the field and for successful clinical translation, including patient selection, identification of responders and non-responders to immunotherapies, implementation of patient immunophenotyping and potential surrogate end points for vascular inflammation. Finally, we provide strategic guidance for the translation of novel targets of immunotherapy into improvements in patient outcomes.

Atherosclerosis, the major cause of cardiovascular disease (CVD), is a chronic inflammatory disease triggered by the accumulation of cholesterol-containing LDL particles in the arterial wall 1 . The gold standard of treatment for atherosclerosis is the prevention of cardiovascular events by targeting modifiable risk factors and the re-establishment of arterial flow by percutaneous or surgical procedures 2, 3 . However, the therapeutic benefit of these strategies on cardiovascular outcomes has stagnated and a huge global burden of CVD remains 4 .

Evidence for the role of inflammation in atherosclerosis has accumulated over the past 35 years (Fig. 1 ). Attilio Maseri was one of the first investigators to foresee the importance of inflammation as a component of the pathogenesis of acute coronary syndromes 5, 6 . The arterial wall is populated by various immune cells, both in healthy individuals and in patients with disease 7, 8 . The innate immune system is the first line of defence against invading pathogens and the innate immune response is usually initiated by pattern recognition receptors, including Toll-like receptors (TLRs) 9, 10 .

The innate immune response induces the activation of antigen-presenting cells such as macrophages and dendritic cells that mediate antigen presentation, co-stimulation and cytokine production in the immune synapse to trigger the adaptive immune response. The adaptive immune response involves B cells and T cells and is slower but more specific and long-lived than the innate immune response. Athero-inflammation involves the activation of both innate and adaptive immune responses, with both inherently linked 8, 11 ( Fig. 2 ). Immune cells in the arteries are activated owing to persistent inflammatory stimuli or a failure in the resolution of inflammation, leading to chronic inflammation, a hallmark of CVD 12 . To understand atherogenesis, we must consider the interplay between cellular immunity and lipid retention 13 and the complex crosstalk between and within immune and non-immune cells, as well as the advantages and disadvantages of the experimental models used in this research field (Box 1).

A unique aspect that sets aside atherogenesis from other chronic inflammatory diseases is the crucial role of Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Suzanne E. Engelen 1,2 , Alice J. B. Robinson 1,2 , Yasemin-Xiomara Zurke 1, 2 and Claudia Monaco 1 ✉ Abstract | Atherosclerosis is a chronic inflammatory disease of the arterial wall, characterized by the formation of plaques containing lipid, connective tissue and immune cells in the intima of large and medium-sized arteries. Over the past three decades, a substantial reduction in cardiovascular mortality has been achieved largely through LDL-cholesterol-lowering regimes and therapies targeting other traditional risk factors for cardiovascular disease, such as hypertension, smoking, diabetes mellitus and obesity. However, the overall benefits of targeting these risk factors have stagnated, and a huge global burden of cardiovascular disease remains. The indispensable role of immunological components in the establishment and chronicity of atherosclerosis has come to the forefront as a clinical target, with proof-of-principle studies demonstrating the benefit and challenges of targeting inflammation and the immune system in cardiovascular disease. In this Review, we provide an overview of the role of the immune system in atherosclerosis by discussing findings from preclinical research and clinical trials. We also identify important challenges that need to be addressed to advance the field and for successful clinical translation, including patient selection, identification of responders and non-responders to immunotherapies, implementation of patient immunophenotyping and potential surrogate end points for vascular inflammation. Finally, we provide strategic guidance for the translation of novel targets of immunotherapy into improvements in patient outcomes.

lipid particles in the induction of atherogenesis. Modified lipoproteins, such as oxidized LDL (oxLDL), trigger the immune response through a unique property, whereby these particles can act as both antigens activating the adaptive immune response 8, 14 and adjuvant molecular patterns activating the innate immune response 15, 16 . In advanced atherosclerosis, complex chronic inflammatory processes result in the generation of a plaque with a thin fibrous cap and a large necrotic core, or in plaque erosion or other plaque morphologies associated with clinical vulnerability to rupture, which lead to ischaemic events 17 . The complexity of inflammation in atherosclerosis has been emphasized by single-cell studies in humans and mice showing the high heterogeneity of vascular leukocytes in atherosclerotic lesions [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . This heterogeneity underscores the importance of targeting specific cell subsets to inhibit atherosclerosis progression while maintaining tissue homeostasis. Superimposing the single-cell transcriptional landscape of leukocytes from mouse and human atherosclerotic plaques will help identify the different pathways, genes or cells that can be used in animal models to study human disease. Moreover, emerging evidence now shows that atherogenesis is a multiorgan process with contributions from organs such as the bone marrow and spleen 28, 29 . In particular, the presence of clonal haematopoiesis of indeterminate potential (CHIP), an age-related process in which certain somatic mutations in bone marrow progenitor cells confer a competitive advantage leading to the expansion of specific cell clones, has been proposed as a risk factor for CVD 30, 31 .

The first proof of the benefits of targeting inflammation in CVD in humans came from the 2017 CANTOS trial 32 , which showed improved clinical outcomes in patients with a history of myocardial infarction (MI) who received treatment with antibodies against IL-1β (canakinumab) compared with those who received placebo (TaBle 1) . This finding was quickly followed by evidence from two clinical trials published in 2019 and 2020 showing that the anti-inflammatory effects of colchicine therapy reduced the risk of cardiovascular events in patients with recent MI 33 or coronary artery disease (CAD) 34 . Evidence for the role of inflammation in CVD has also been described in other disease settings. Patients with chronic inflammatory diseases such as lupus or rheumatoid arthritis (RA) have an increased risk of CVD (tenfold and twofold, respectively) compared with healthy controls, and this risk significantly correlates with the magnitude of systemic inflammation 35 . Moreover, checkpoint inhibitor therapies used for several cancer types to improve tumour surveillance by the immune system are associated with an increased risk of CVD, adding to the challenges in the cardio-oncology field 36, 37 . Together, these studies highlight immunotherapeutics as the next step in CVD therapy that will provide an opportunity to surpass the ceiling reached with the current management of classic risk factors for CVD to address the residual cardiovascular risk 38 . At present, the challenge lies in identifying crucial effectors of atherosclerosis-specific inflammation among the plethora of inflammatory mediators while sparing the host defence.

In this Review, we discuss the therapeutic potential of targeting the immune system in atherosclerosis. First, we provide an overview of immune cells involved in CVD. Next, we summarize the published and ongoing clinical trials targeting the immune system in athero sclerosis and identify important challenges that need to be addressed to advance the translation of novel immuno therapeutics into the clinic. Finally, we highlight the new therapeutic targets emerging from preclinical studies with the biggest potential for translational pay-off in the medium term.

In this section, we summarize the functional diversity of innate and adaptive immune cells in atherosclerosis and refer to previous reviews for further in-depth discussion. The role of platelets and other non-immune cells in inflammation have been previously reviewed [39] [40] [41] .

Monocytes are present in the blood, bone marrow and spleen during homeostasis. Monocytes can be classified into two main populations: classical monocytes (Ly6C high in mice and CD14 + CD16 − in humans) and non-classical monocytes (Ly6C low in mice and CD14 low CD16 + in humans). In atherosclerosis, classical monocytes are recruited to atherosclerotic plaques after engagement of the chemokine receptors CCR2, CCR5 and CX3CR1 (reFs 11, 42 ). In the plaque, monocytes differentiate into dendritic cells and macrophages that show high functional and phenotypic heterogeneity 43 . In both mice 42, 44 and humans 45 , an increase in the blood monocyte pool is associated with increased severity of atherosclerosis. Preclinical studies in mice have demonstrated that splenic Ly6C high monocytes contribute to both the growing atheroma and plaque instability 29, 46 . However, monocyte recruitment also has an important role in atherosclerosis regression 47 , and 'patrolling' Ly6C low monocytes, which are derived from Ly6C high monocytes, are important for endothelial cell maintenance 48 . Hypercholesterolaemia, stress, inflammation and other

• Inflammation is an important component of the pathophysiology of cardiovascular disease; an imbalance between pro-inflammatory and anti-inflammatory processes drives chronic inflammation and the formation of atherosclerotic plaques in the vessel wall. • Clinical trials assessing canakinumab and colchicine therapies in atherosclerotic cardiovascular disease have provided proof-of-principle of the benefits associated with therapeutic targeting of the immune system in atherosclerosis. • The immunosuppressive adverse effects associated with the systemic use of antiinflammatory drugs can be minimized through targeted delivery of anti-inflammatory drugs to the atherosclerotic plaque, defining the window of opportunity for treatment and identifying more specific targets for cardiovascular inflammation. • Implementing immunophenotyping in clinical trials in patients with atherosclerotic cardiovascular disease will allow the identification of immune signatures and the selection of patients with the highest probability of deriving benefit from a specific therapy. • Clinical stratification via novel risk factors and discovery of new surrogate markers of vascular inflammation are crucial for identifying new immunotherapeutic targets and their successful translation into the clinic.

www.nature.com/nrcardio R e v i e w s risk factors for atherosclerosis can induce emergency haematopoiesis, including extramedullary haematopoiesis in the spleen 29 , and contribute to disease progression by skewing haematopoietic stem cells in the bone marrow towards monopoiesis 29, 44, 49 .

Two distinct resident macrophage populations are found in mouse arteries, one in the intima and the other in the adventitia 50 . Both macrophage populations originate from embryonic precursors and their survival depends on the presence of colony-stimulating factor 1. Resident adventitial macrophages are replenished by bone-marrow-derived monocytes in the period immediately after birth and are maintained by local proliferation in adulthood 51 . In atherogenesis, monocytes reconstitute the population of resident macrophages in the arterial intima during early stages of atherosclerosis 50 , whereas local proliferation of lesional macrophages contributes to macrophage accumulation in advanced lesions 52 . In both health and disease, adventitial macrophages expressing lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE1) prevent unfavourable arterial remodelling, largely through the regulation of collagen production in medial vascular smooth muscle cells (VSMCs) 53 . Arterial intima-resident macrophages have a pro-atherogenic function, and ablation of these macrophages prevents lesion formation 50 . A subset of LYVE1 + vascular macrophages expressing the innate immune receptor C-type lectin CLEC4A2 has anti-atherogenic functions and the ablation of this macrophage population increases lesion formation 54 . Arterial macrophages have distinct functional and ontogenetic signatures and this plasticity reflects the heterogeneous environment of atherosclerotic plaques, which is increasingly being appreciated. Genetic lineage tracing and monocyte fate mapping studies have started exploring the contributions of monocytes to specific macrophage subpopulations in atherosclerosis 20, 47 and have helped to understand how local progenitor cells and proliferation of resident macrophages contribute to plaque progression 50, 52, 55 . Three main macrophage popu lations with different inflammatory properties have been identified in single-cell studies of human 19 and mouse 18, 27 atherosclerotic plaques, suggesting that macrophage heterogeneity in the plaques cannot be explained simply by the M1-M2 macrophage polarization paradigm 56 . Strikingly, a pro-inflammatory The timeline shows the main milestones in the past four decades of research into the role of inflammation in atherosclerosis. In the 1980s, the introduction of immunohistochemical techniques to study atherosclerotic plaques provided evidence of HLA-DR expression in human atherosclerotic plaques, followed by identification of monocytes, macrophages and T cells in the plaque 29, 44, [263] [264] [265] [266] [267] [268] [269] . In the 1990s, studies showed the presence of pro-inflammatory cytokines, such as tumour necrosis factor (TNF), in atherosclerotic plaques [270] [271] [272] [273] [274] , and the association between high plasma C-reactive protein (CRP) levels and coronary artery disease (CAD) 5, 275 . During this decade, the first mouse models of hypercholesterolaemia with an inflammatory gene knockout were developed 274, 276, 277 and titres of antibodies against oxidized LDL (oxLDL) in the serum were shown to predict cardiovascular disease outcomes 278 . In the 2000s, studies demonstrated the association between increased levels of inflammatory markers and increased risk of cardiovascular events 279, 280 . An increased risk of cardiovascular disease was shown in patients with inflammatory diseases [281] [282] [283] , and several studies demonstrated the association between elevated levels of CRP, IL-6 and TNF in the plasma and worse clinical outcomes in patients with cardiovascular disease 115, 127, 284, 285 . This finding led to the introduction of inflammation as a therapeutic target in cardiovascular disease 286 . In the late 2010s, studies showed that immune checkpoint inhibitor treatment increased the risk of cardiovascular disease in patients with cancer 287, 288 . In the past decade, clinical trials investigated whether targeting inflammation in cardiovascular disease is beneficial 32, 34, 135 . Numerous studies also demonstrated the involvement of the bone marrow in atherosclerosis 172, 177, 178 and performed single-cell analysis of plaque immune cells 19, 25 . Preclinical discoveries are shown in blue boxes and clinical discoveries in red boxes. MI, myocardial infarction; VSMC, vascular smooth muscle cell.

NaTure reviews | Cardiology R e v i e w s 0123456789();: macrophage population found in mice and humans expresses high levels of IL-1β 18, 19 , a well-recognized immune target in atherosclerosis, further highlighting the relevance of this cytokine for atherosclerosis progression. Another population of the identified macrophage subsets has a more resident-like phenotype and is enriched in transcripts of proteins involved in antigen presentation and endocytosis 18, 25 . Foam cells are a hallmark of atherosclerosis. These cells are derived from macrophages, dendritic cells and VSMCs 57 . Foam cells drive necrotic core formation through uptake of intraplaque lipids, which leads to increased endoplasmic reticulum stress and cell death 57 . A single-cell study of mouse atherosclerotic lesions showed that plaque Trem2 high macrophages, a subset that has also been identified in adipose tissue, express genes associated with lipid handling and have a profile consistent with a foamy macrophage phenotype 27 . TREM2 high macrophages in human and mouse atherosclerotic lesions do not express genes encoding inflammatory factors, suggesting that these subsets have a homeostatic lipid-handling role in the plaques 18, 22, 25, 58 . The profile of this macrophage subset is consistent with evidence showing that intracellular accumulation of desmosterol, a precursor in cholesterol biosynthesis, maintains macrophage homeostasis through the activation of transcription of liver X receptor target genes and the suppression of inflammation 18, 22, 25, 58 . This discovery draws important parallels between the pathophysiology of CVD and obesity, highlighting a common blueprint between the two most prevalent metabolic diseases at present 59 In medium and large arteries, haemodynamic forces create areas of low shear stress that are often predictors of atherosclerotic plaque location. As the atherosclerotic plaque begins to form, circulating apolipoprotein B (ApoB)-containing lipoproteins (ApoB-LP) and ApoB peptides enter the subendothelial space, where they can be modified and recognized by innate immune cells as danger signals. These danger signals activate Toll-like receptor (TLR) signalling and the inflammasome in innate immune cells, eliciting responses that drive inflammation, including production and secretion of cytokines, release of neutrophil extracellular traps (NETs), upregulation of co-stimulatory molecules and promotion of monocyte recruitment to the plaque 289 . Macrophages derived from monocyte differentiation, local proliferation or from transdifferentiation of vascular smooth muscle cells (VSMCs) take up lipoproteins present in the plaque and become lipid-laden foam cells that lay the foundation for the formation of the plaque necrotic core. At the immune synapse, antigen-presenting cells (APCs), including macrophages, dendritic cells and B cells, present lipid antigens to invariant natural killer T (iNKT) cells and peptide antigens to T cells, the latter engaging adaptive T cell and B cell responses. Antigen presentation occurs in the plaque and in secondary lymph organs, such as the lymph node 8 . Together, all these processes contribute to endothelial dysfunction, leading to further aggravation of inflammation through continued monocyte recruitment, increased uptake of lipoproteins adding to the plaque lipid burden, VSMC activation and proliferation, and fibroblast migration contributing to fibrous cap formation. ECM, extracellular matrix; IFN, interferon; MHC, major histocompatibility complex; ROS, reactive oxygen species; TCR, T cell receptor; T H 1, T helper 1; TNF, tumour necrosis factor; T reg cell, regulatory T cell. of lipid-driven inflammation. Further studies are warranted to reconcile inflammatory and lipid drivers of the disease. Another aspect of plaque macrophage biology to consider is the role of these cells in plaque rupture and thrombosis through the production of matrix metalloproteinases and tissue factor 61 , and the coordination of intraplaque efferocytosis, a crucial mechanism for resolving inflammation in atherosclerosis 62 (Box 2).

Dendritic cells are another crucial cell type driving atherosclerotic plaque inflammation that bridges the innate and adaptive immune responses. Dendritic cells can be classified into three main subsets: plasmacytoid dendritic cells, type 1 conventional dendritic cells (cDC1s) and type 2 conventional dendritic cells (cDC2s). Plasmacytoid dendritic cells are generally located in blood and lymphoid tissues. After encountering pathogens, these cells produce large amounts of type I interferon (IFN). By contrast, conventional dendritic cells are found in lymphoid and non-lymphoid sites. cDC1s are involved in cross-presentation of antigens and drive cytotoxic immune responses, whereas cDC2s are involved in T cell priming 63 .

In humans, plaque dendritic cell numbers positively correlate with plaque vulnerability 64 . Dendritic cells have been found to have both pro-atherogenic and anti-atherogenic functions in mouse models, as reviewed previously 8 . Dendritic cells elicit an adaptive immune response that encompasses both T cells and B cells 8 . During atherosclerosis regression in mice, dendritic cells can leave the lesions and migrate to the lymphatic tissue in a process mediated by the chemokine ligands CCL19 and CCL21 and their receptor CCR7 on the surface of dendritic cells 65 . Dendritic cells expressing CCL17 have a pro-atherogenic role in mice 66 .

Laboratory mice have provided invaluable insights into the mammalian immune system, diseases and drug development. These models are economical, easy to breed and straightforward to manipulate genetically and for these reasons, they are here to stay. The generation of Apoe −/−290 and Ldlr −/−291 mouse models has led to scientific advances in the field of lipoprotein metabolism as well as in research on inflammation in atherosclerosis, and validated the discovery of PCSK9 as a novel therapy 292, 293 . However, the translation of beneficial responses to therapeutics from mice to humans has not always been successful [294] [295] [296] [297] .

The cardiovascular system of mice and humans differs in the levels of shear stress in the vasculature 298 , the degree of fibrosis 299 and the content of T cells (higher in humans 25 ). Furthermore, atherosclerotic lesions in mice form predominantly at the aortic root, a pattern observed in patients with familial hypercholesterolaemia but not relevant to the general population 299 . Plaque rupture frequency in mice is very low and when it happens spontaneously (usually in the brachiocephalic artery), the rupture is not at the same site as in humans (carotid artery) 300 . Moreover, only a few genes linked to atherosclerosis in mice have shown a genetic association with human atherosclerosis, raising questions as to the use of mouse models of atherosclerosis 301 . As a result, to study the spectrum of human cardiovascular disease thoroughly we have to use several experimental models.

The immune system of mice and humans is also dissimilar; mice have higher lymphocyte levels (70-90%) and fewer neutrophils (10-25%) in the blood. Toll-like receptor (TLR) expression, antibody subsets, levels of defensins and nitric oxide production are also different in mice and humans, as reviewed previously 294 . In addition, many cytokines and chemokines in humans have no known orthologues in mice and vice versa 295 . These differences are partly attributable to variations in protein expression and signalling. Genomic comparisons revealed substantial transcriptional overlap between mice and humans but raised noteworthy differences 302 . Moreover, the immune response varies between mouse strains as a result of genetic variations and polymorphisms arising from genetic drift and/or intentional breeding 303 .

Pig models have similar cardiovascular anatomical features to and higher genetic homology with humans. For instance, as in humans, pigs have ten TLRs (TLR1-10) and duplication of the IL1B gene, and pig TLRs have significant homology with their human counterparts 304 . However, distinguishing dendritic cells from macrophages and B cells in pigs is difficult owing to common markers in these cell types, and variations in the morphology and function of neutrophils have been reported between pig breeds 305 . Lymph node histology is also different between pigs and humans; in pigs, the medullary tissue is located in the periphery and the cortical part in the central area 305 . Finally, there is a severe lack of reagents for pig models compared with their availability for humans and mouse models. Altogether, the study of the immune system and its role in cardiovascular diseases in pig models presents challenges.

Organoid systems and lab-on-a-chip technology are being devised to fill the gap in translation between mouse models and humans 306 . In the meantime, we strive to improve mouse models. To reduce variability, laboratory mice are kept in specific pathogen-free conditions, leading to a low density of mature T cells, scarceness of neutrophils and low lipopolysaccharide responsiveness compared with mice in the wild, which more closely resembles the human immune system 294, 307, 308 . Therefore, part of the problem is not inherent in the use of mouse models per se but how we use them. Perhaps better models will emerge by dialling back our efforts towards pathogen-free environments. Moreover, humanized mice are a powerful tool to improve research into human cardiac disease 309 .

In summary, mouse models are still the foundation of basic research and offer too many advantages to be discarded. Albeit useful, no organoid or lab-on-a-chip system can fully reproduce the advantage of a structured immune system. Therefore, several questions must be considered when choosing a model: What aspect of human cardiovascular disease is addressed with the model? Does the model recapitulate the human immune response in the disease condition or a particular stage of disease? Is the species or strain appropriate to model the question? Are there reagents available to study the immune system? How could the genetic background influence the study outcome? Considering these questions, we need to keep learning from a variety of biological systems, using each one to address the appropriate question to which it can provide the answer.

NaTure reviews | Cardiology R e v i e w s 0123456789();: CD103 + cDC1s can promote atheroprotective regulatory T (T reg ) cell responses 67 . Loss of myeloid differentiation factor 88 (MyD88) signalling in CD11c + dendritic cells leads to loss of T reg cells and increased atherogenesis in mice 68 . By contrast, plasmacytoid dendritic cells have been reported to have both pro-atherogenic and anti-atherogenic roles in mice, possibly owing to subtle cellular heterogeneity in this subset 69, 70 .

Neutrophils are involved in all stages of atherosclerosis 71 . In mice, neutrophil depletion reduces atherosclerosis, whereas increased levels of circulating neutrophils exacerbate plaque formation, suggesting a role of this cell type in lesion development 72 . Neutrophils promote vascular inflammation through the secretion of reactive oxygen species, which leads to increased permeability of the endothelial cell barrier 73 . Neutrophils attract monocytes via secretion of chemotactic molecules and can activate macrophages via extrusion of their nuclear material as neutrophil extracellular traps (NETs) 74 . NETs contain histone H4, which binds to VSMCs and induces cell lysis, resulting in plaque destabilization 75 . In addition, NETs induce plaque erosion and platelet aggregation, leading to thrombosis 76 . Overall, neutrophils have a pro-atherogenic role. However, during thrombotic events, neutrophils have reparative functions through the promotion of endothelial repair and angiogenesis 77 .

progression, as reviewed previously 78, 79 . A mass cytometry study revealed that T cells outnumber macrophages in human carotid artery plaques 25 , in contrast to plaques in mice, in which the overall proportion of T cells is lower 24 . T cells in human atherosclerotic plaques show more activation-related and exhaustion-related gene expression than peripheral blood T cells. High expression of the inhibitory molecule PD1 as a consequence of chronic antigen stimulation can result in inefficient T cell effector function and dysregulation of the immune response within the plaque 19, 25 . Once activated, T cells directly mediate effector functions in the arterial wall or help B cells produce antibodies. CD4 + T cells are the most abundant T cells in mouse atherosclerotic plaques, and are polarized predominantly towards a pro-inflammatory phenotype (T helper 1 (T H 1) cells) 79 . CD4 + T cells have been shown to both protect against and promote atherogenesis depending on the subset involved. T H 1 cells have been consistently shown to have pro-atherogenic roles, whereas T reg cells are thought to have atheroprotective roles via IL-10 and TGFβ secretion 78 78 . Phenotyping of CD4 + T cells in a mouse model of atherosclerosis with the use of single-cell RNA sequencing revealed a CD4 + T cell population 80 that shared transcriptional similarities with apolipoprotein B (ApoB)-reactive CD4 + T cells 81 . During atherosclerosis progression, ApoB-reactive CD4 + T cells undergo a transition from a T reg cell to a pro-inflammatory phenotype, which might contribute to further disease progression 81 .

CD8 + T cells in atherosclerotic lesions have also been found to have dual functions, with pro-atherogenic effects mediated by IFNγ production and macrophage activation, and atheroprotective effects via B cell modulation 78 . CD8 + T cells in mice have been identified as drivers of plaque inflammation and apoptosis, promoting unstable plaque phenotypes and plaque erosion 82, 83 . CD8 + T cells outnumber CD4 + T cells in advanced human atherosclerotic plaques 25, 82 , and an increase in CD8 + T cell numbers in blood is associated with the presence of CAD 84, 85 . Invariant natural killer T (iNKT) cells are a distinct subset of T cells that express unique invariant T cell receptors and natural killer cell surface molecules, such as CD161 (also known as NK1.1 in mice) and killer cell immunoglobulin-like receptors (analogous to the Ly49 family in mice) 86 . Given the central role of lipids in athero sclerosis, iNKT cells are a relevant cell type because they respond to lipid antigens presented by CD1d on antigen-presenting cells. In mice, iNKT cells are considered to be pro-atherogenic owing to their production of pro-inflammatory cytokines such as IFNγ 86 . In humans, rupture-prone plaques have higher numbers of iNKT cells than stable plaques 87 but the exact mechanism underlying this observation is unknown.

B cell subpopulations make different contributions to atherogenesis 88 . B cells are central to humoral immunity and mediate the production of antibodies against oxidation-specific epitopes to help dampen inflammation. B cells are classified into two lineages: B1 cells, which are mainly produced in the fetal liver, and B2 cells, which originate in the bone marrow. B1 cells are further subdivided into B1a and B1b subsets. B2 cells can differentiate into transitional (T1 and T2 marginal zone progenitor) B cells, marginal zone B cells, follicular B cells and antibody-secreting plasma cells 88 .

The balance between pro-inflammatory and anti-inflammatory immune processes is important for tissue homeostasis and to control inflammation. A failure to resolve acute inflammation results in the development of chronic inflammation, as seen in atherosclerosis. Crucial mechanisms in the resolution of inflammation in atherosclerosis involve efferocytosis and a rebalance of the levels of pro-inflammatory lipid mediators towards specialized pro-resolving mediators (SPMs). Non-specific targeting of inflammation in cardiovascular disease might affect immune subsets with homeostatic functions and induce the inhibition of endogenous plaque-resolving immune processes, such as efferocytosis.

Defective efferocytosis and lack of immunomodulation promote an inflammatory environment in the atherosclerotic plaque, the formation of the necrotic core and plaque destabilization owing to secondary necrosis of apoptotic cells 62 . Efferocytosis is mediated through phagocytic receptors, such as tyrosine-protein kinase MER (MERTK) or LDL-receptorrelated protein 1 (LRP1), and apoptotic cell ligands [310] [311] [312] . In atherosclerosis, impaired efferocytosis can be attributed to the downregulation or cleavage of efferocytosis receptors 310, 312 and dysregulated expression of 'eat me' signals 313, 314 . Atherosclerotic mice with increased MERTK expression have higher levels of efferocytosis and less necrotic core formation than control Ldlr −/− mice 310, 311 . Loss of LRP1 in macrophages or haematopoietic cells in atheroprone mice leads to increased lesion area and necrotic core size 315 , highlighting the potential of therapies aimed at increasing efferocytosis. One avenue for increasing efferocytosis is masking the 'don't eat me' signal CD47 on apoptotic cells. Blocking CD47 with a neutralizing antibody improved efferocytosis and ameliorated atherosclerosis in Apoe −/− mice 314 . Drugs targeting CD47 (Hu5F9-G4 and TTI-621) are currently being tested in clinical studies as cancer therapies 316, 317 . However, the use of anti-CD47 in a clinical setting might have various adverse effects because of the role of CD47 in the regulation of other cellular processes 318 , such as anaemia owing to high CD47 expression on haematopoietic stem cells and erythrocytes 319 . In addition, total loss of CD47 or its ligand thrombospondin, which is associated with the regulation of inflammatory responses rather than efferocytosis, increased the size of the necrotic core in mice 320 . Therefore, the pharmacological properties of the antibody and target accessibility should be considered before advancing this therapy into the clinical arena. Of note, concomitant inhibition of CD47 and tumour necrosis factor (TNF) using anti-CD47 antibody therapy and commercially available anti-TNF antibodies, such as infliximab or etanercept, offers a synergistic benefit in the clearance of apoptotic cells in mice 314 . The observation that anti-TNF therapy reduces the risk of future cardiovascular events in patients with rheumatoid arthritis 321 provides a strong rationale for combining anti-inflammatory and pro-efferocytic therapies for the treatment of advanced atherosclerosis.

Mediators involved in the resolution of inflammation in atherosclerosis include IL-10, annexin A1 and SPMs, such as resolving D1, 15-epi-lipoxin A4 and resolvin E1 (reF. 322 ). Chronic inflammation in mouse and human atherosclerotic plaques is characterized by an imbalance between SPMs and pro-inflammatory mediators, such as leukotrienes 323 . In addition, a low resolvin D1 to leukotriene ratio in saliva has been proposed as a biomarker of the presence of non-resolving inflammation 324 .

In the atherosclerotic plaque, lipid and peptide SPMs signal through N-formyl peptide receptor 2 (FPR2) and chemokinelike receptor 1 (CMKLR1), which are both G protein-coupled receptors. Systemic administration of SPMs, including resolvin D1, 15-epi-lipoxin A4, Ac2-26 (a synthetic analogue of annexin A1) and resolvin E1, reduced atherosclerosis in mouse and rabbit models of advanced atherosclerosis 249, 323, [325] [326] [327] [328] . These studies highlight that restoring the balance of pro-inflammatory and pro-resolving mediators to induce the resolution of inflammation is an exciting therapeutic avenue, especially given that atherosclerosis in a clinical setting is usually treated once plaques and non-resolving inflammation have been established. Resolvin E1 analogues have been tested in a phase II trial for the treatment of ocular inflammation but did not improve outcomes compared with placebo 329 . However, before moving into a clinical setting in cardiovascular disease, the effect of activation of immunosuppressive mechanisms should be evaluated. Most of the above-mentioned mediators have systemic roles in maintaining tissue homeostasis. However, specific delivery of Ac2-26 using monocyte-macrophage-targeting nanoparticles increased plaque stability in mice 249 . Therefore, selective targeting of specific pro-resolving or pro-inflammatory cell types in atherosclerosis will most probably mediate the most beneficial outcomes in the clinic.

In atherosclerosis, B cells are not always found in the plaque and are more commonly localized in the adventitia or in node-like structures, referred to as tertiary lymphoid organs, that form in the adventitia as a result of chronic inflammation 79 . B1 cells have been described as atheroprotective in mice owing to the production of IgM antibodies that block the uptake of oxLDL by macrophages in lesions 16, 89 . By contrast, B2 cells have been shown overall to be pro-atherogenic, through antibody responses formed via germinal centre B cell reactions that further drive adaptive immunity 88 . In mice fed a high-cholesterol diet, subsets of B2 cells with atheroprotective functions arise in secondary lymphoid organs, such as the lymph node (T2 marginal zone progenitor B cells) 90 and the spleen (marginal zone B cells) 91 . These subsets act either through PDL1-mediated suppression of T follicular helper cells 91 or via IL-10, although the role of IL-10 varies in different mouse models (IL-10 was shown to have a role in Apoe −/− mice 90 but not in Ldlr −/− chimeric mice 92 ) and is dependent on the microbiome 93 and the radioresistance of B cell subsets 94 .

Over the past 5 years, promising results from clinical trials targeting inflammation in CVD have been reported. In this section, we summarize the positive phase III trials, promising phase II studies, ongoing trials and trials with neutral results, and the lessons learnt from these studies (Fig. 3) .

Two immunotherapeutics have been successful in improving the cardiovascular outcomes of patients with CVD: canakinumab 32 and colchicine 33, 34, 95 (TaBle 1) .

Canakinumab. The CANTOS trial 32 was a double-blind, randomized, controlled trial investigating the effects of canakinumab, a monoclonal antibody against the proinflammatory cytokine IL-1β, in patients with recent MI. In total, 10,061 patients with a history of MI who were receiving optimal management for cardiovascular risk factors and had high-sensitivity C-reactive protein (hsCRP) levels of >2 mg/l were randomly assigned to receive canakinumab or placebo. Canakinumab was administered subcutaneously at doses of 50 mg, 150 mg or 300 mg every 3 months. Patients were followed up for a median of 3.7 years. The 150-mg canakinumab dose led to a significantly lower rate of recurrent cardiovascular events than placebo, independently of lipid-level lowering (HR 0.85, 95% CI 0.74-0.98; P = 0.021) 32 . No effect was observed on total mortality, owing to a small but significant increased risk of infection with canakinumab. Notably, among patients receiving canakinumab, those with a reduction in on-treatment hsCRP levels to <2 mg/l benefited the most from the treatment, and the effect of canakinumab at reducing hsCRP levels was dose-dependent 96 . A subanalysis extended the scope of the effects of canakinumab beyond IL-1β by showing that the modulation of plasma IL-6 levels is associated with the beneficial effects of canakinumab in reducing the risk of cardiovascular events 97 . Moreover, canakinumab reduced cancer mortality 98 . The CANTOS trial demonstrated for the first time the proof-of-principle that therapeutic targeting of the immune system can be beneficial for cardiovascular outcomes in patients.

Colchicine, which is widely used for the treatment of gout and pericarditis, decreases inflammation by inhibiting cytoskeletal microtubule formation 99, 100 . Colchicine has broad cellular effects, including reduction of monocyte and neutrophil motility and inhibition of inflammasome assembly in vitro 101 . The LoDoCo2 trial 34 included 5,522 patients with stable chronic CAD. After 1 month of open-label use of colchicine (0.5 mg once daily), patients were randomly assigned to receive colchicine or placebo and followed up for a median of 28.6 months. Patients receiving colchicine had a 31% reduction in the incidence of the primary composite end point of cardiovascular death, MI, ischaemic stroke and ischaemia-driven coronary revascularization compared with patients receiving placebo (HR 0.69, 95% CI 0.57-0.83; P < 0.001). Unfortunately, data on the effects of colchicine on inflammatory markers are not available. The results of this trial are consistent with those of two phase II trials investigating colchicine, LoDoCo 95 (in patients with stable chronic CAD) and COLCOT 33 (in patients with MI), and provide further support for the potential benefits of anti-inflammatory therapy in patients with acute coronary disease. Taken together, these trials demonstrated that anti-inflammatory therapies are efficacious in reducing cardiovascular events in patients with stable CVD. Although CANTOS and LoDoCo2 have not yet changed the treatment strategy in cardiovascular risk management in clinical practice, these trials are a crucial milestone for the clinical translation of immunomodulatory therapeutics in CVD. Both treatments target innate immunity, offering proof in humans of the importance of the innate response of the immune system in triggering inflammation in atherosclerosis.

Several cytokine blockers have shown promising results in phase II trials (TaBle 2) . Cytokine blockers are the first line of biologics for the treatment of chronic inflammatory diseases, including RA, inflammatory bowel disease and psoriasis [102] [103] [104] . Therefore, an arsenal of potential therapeutics for CVD is available, some of which will soon be available as generic drugs (such as tumour necrosis factor (TNF) blockers).

IL-1 is a pro-inflammatory cytokine that drives inflammation in atherosclerosis 105 . Both isoforms of IL-1, IL-1α and IL-1β, are involved in atherosclerosis. Studies in mice have shown that IL-1α has a role in the remodelling of arteries during early atherogenesis, whereas IL-1β mainly drives vascular inflammation in later stages of atherosclerosis 106 . However, IL-1β had a protective role in advanced atherosclerosis in mice through the promotion and maintenance of a fibrous cap rich in VSMCs and collagen 107 . Additionally, IL-1α forms a link between the immune system and coagulation through the activation of IL-1α by thrombin, underscoring the importance of this isoform in the pathogenesis of adverse cardiovascular events 108 . In humans, the levels of IL-1β in the coronary arteries are higher in patients with CAD than in patients with nonischaemic cardiomyopathy 109 , and this cytokine is considered to be therapeutically tractable. Several options are available for IL-1 blockade, including canakinumab (selective IL-1β targeting), anakinra (an IL-1 receptor antagonist, which thereby targets IL-1α and IL-1β) and xilonix (a monoclonal antibody specifically targeting IL-1α). In two separate studies, therapy with anakinra significantly reduced hsCRP levels in the acute setting in patients with ACS compared with placebo 110, 111 . Therapy with xilonix plus standard of care showed a non-significant trend towards a reduction in restenosis and the incidence of major adverse cardiovascular events Fig. 3 | Targeting the immune system in atherosclerosis. a-d | Immunotherapies for the treatment of atherosclerosis that showed benefit (green), no benefit (red) or potential benefit (yellow) in reducing inflammation or cardiovascular events in clinical trials or currently being tested in ongoing clinical trials (blue) are shown. Therapeutics targeting innate immunity include IL-1 inhibitors, IL-6 inhibitors, tumour necrosis factor (TNF) blockers and p38 inhibitors (panel a). Therapeutics targeting adaptive immunity include local proliferation inhibitors in drug-eluting stents and low-dose IL-2 targeting regulatory T (T reg ) cells (panel b). Therapeutics targeting lipoproteins to reduce inflammation include antibodies against oxidized LDL (oxLDL), lipoprotein-associated phospholipase A2 (Lp-PLA 2 ), secretory phospholipase A2 (sPLA 2 ) and lectin-like oxidized LDL receptor 1 (LOX1) (panel c). Therapeutics with broad immunosuppressive effects include colchicine, low-dose methotrexate, glucocorticoids and hydroxychloroquine (panel d). See TaBles 1,2 and 3 and Supplementary Table 1 for further details. e-g | Overview of therapeutics in preclinical development targeting innate immunity (panel e), co-stimulation pathways (panel f) and B cell and T cell regulation (panel g). APC, antigenpresenting cell; ApoB, apolipoprotein B; BAFF, B cell activating factor; BCMA, B cell maturation antigen; BTLA, B and T lymphocyte attenu ator; CCR, C-C chemokine receptor; CD30L, CD30 ligand; CD40L, CD40 ligand; CTLA4, cytotoxic T lymphocyte antigen 4; CVD, cardiovascular disease; GLUT1, glucose transporter 1; HDAC, histone deacetylase; HSPC, haemato poietic stem and progenitor cell; IRF5, interferon regulatory factor 5; OX40L, OX40 ligand; PPARγ, peroxisome proliferator-activated receptor-γ; siRNA, small interfering RNA; SPM, specialized pro-resolving mediators; TLR, Toll-like receptor; TRAF6, tumour necrosis factor receptor-associated factor 6.

NaTure reviews | Cardiology R e v i e w s 0123456789();: compared with standard of care only in patients undergoing percutaneous femoral artery revascularization 112 . Whereas the CANTOS trial highlighted the relevance of targeting IL-1β in stable CAD, these studies illustrate the importance of IL-1 as a target in the acute setting of thrombotic events. Additional studies in larger patient groups should be performed to further assess the effect of these therapeutics on cardiovascular outcomes.

IL-6 is a pro-inflammatory cytokine involved in the innate immune response and a downstream mediator of a cytokine cascade featuring TNF and IL-1. IL-6 is a central stimulus for the acute phase response. In particular, IL-6 stimulates the production of CRP, among other acute phase reactants, in hepatocytes 113 . IL-6 signalling contributes to atherosclerosis and plaque destabilization in mice 114 . Data from humans show that elevated IL-6 levels in the plasma are associated with an increased risk of MI, and genetic studies have provided evidence of a causal role for IL-6 receptor signalling in CVD [115] [116] [117] . Therapy with tocilizumab, a monoclonal antibody targeting the IL-6 receptor, reduced hsCRP levels in patients with ST-segment elevation MI (STEMI) 118 or non-STEMI 119 compared with placebo. Tocilizumab therapy also significantly increased the myocardial salvage index in patients with STEMI 118 ; however, the absolute difference between the tocilizumab and placebo groups was only 5.6%, meaning that this increase might be of limited clinical relevance. In a phase II trial published in 2021, IL-6 blocking with the antibody ziltivekimab reduced hsCRP levels in patients with chronic kidney disease, who are at high risk of atherosclerosis 120 . These studies demonstrate the efficacy of IL-6 blockade for inflammation reduction. Follow-up studies, including the ZEUS trial 121 , will provide a more complete picture of the clinical relevance of IL-6-targeted therapies in CVD.

Alternatives to IL-1 and IL-6 blockade include TNF or IL-23 blockers, given that preclinical and clinical research has demonstrated a proatherogenic role for these cytokines [122] [123] [124] . TNF is a pro-inflammatory cytokine and is produced by several cells involved in atherosclerosis, including macrophages and VSMCs 125 . In mice, TNF deficiency reduced atherogenesis 126 . In humans, TNF is present in atherosclerotic plaques and the levels of TNF in peripheral blood predict future coronary events in patients with MI 125, 127 .

In observational studies in patients with arthritis, inflammation was a strong risk factor for cardiovascular events and TNF blockade resulted in reduced atherogenesis and lower incidence of cardiovascular events compared with patients with arthritis who did not receive TNF-blocking therapy 35 . However, in clinical trials in patients with heart failure, TNF blockade had no efficacy or even worsened the clinical outcome 128, 129 . Therefore, TNF blockers might not be suitable for patients with substantial deterioration of left ventricular systolic function.

IL-23 is present in human atherosclerotic plaques, and high plasma levels of IL-23 are associated with increased mortality in patients with carotid artery stenosis 123 . Studies in mice have shown that IL-23 drives T H 17 cell function, contributing to the aggravation of atherosclerosis [130] [131] [132] . Despite the pro-atherogenic role of IL-23 in mice, several meta-analyses of studies in patients with psoriasis showed either no effect or possible worsening of cardiovascular outcomes after treatment with IL-23 blockers (ustekinumab and briakinumab) compared with placebo 133, 134 . These studies were primarily designed to assess the effect of the IL-23 blockers on psoriasis and, therefore, conclusions cannot be drawn about their effect on inflammation in atherosclerosis. Other alternative therapeutic targets currently being tested in trials, including hydroxychloroquine and low-dose IL-2, are discussed in Box 3 and TaBle 3 .

Several strategies for targeting inflammation in CVD have been tested in clinical trials but have not resulted in the reduction of inflammation markers and/or cardiovascular events (Supplementary Table 1 ). Notable examples are methotrexate and a p38 inhibitor, which did not reduce cardiovascular events or mortality in patients with CVD 135, 136 . The majority of the trials that did not show efficacy of the drug being tested included unselected patient cohorts; therefore, a potential explanation for the lack of efficacy might be the heterogeneity of the patient group. The CANTOS trial 32 was the first trial to take a step towards the use of precision medicine by specifically selecting patients with an increased residual inflammatory risk (measured as hsCRP >2 mg/l). However, the trials investigating colchicine also included unselected patient groups and did show beneficial effects on cardiovascular outcomes 33, 34 . This finding illustrates that failure to demonstrate efficacy might also be mechanism-based and that inhibiting inflammation in CVD is effective provided the correct inflammatory target or drug is chosen.

The variability of disease settings in clinical trials of CVD might explain the lack of beneficial effects of p38 inhibitors. p38 is an intracellular kinase that is activated in CVD by several stressors, such as oxLDL and hypertension, and is involved in the stabilization of mRNA encoding several inflammatory mediators that are crucial in CVD 137, 138 . The first study of the p38 inhibitor losmapimod in CVD included patients with stable atherosclerosis 139 . Vascular inflammation was assessed with fluorodeoxyglucose (FDG) PET-CT imaging. Losmapimod therapy did not significantly reduce the overall uptake of FDG in the index vessel compared with placebo but reduced inflammation in the most inflamed regions 139 . However, losmapimod had no effect on clinical outcomes in subsequent trials that included larger cohorts of patients with acute MI 136, 140 , suggesting that p38 might have a selective role in chronic stable CVD, which is consistent with the role of p38 in prolonging inflammatory responses via modulation of mRNA stability 138 .

Other studies have also used FDG PET-CT imaging to assess vascular inflammation, such as the GLACIER trial 141 .

Hydroxychloroquine is an antimalarial and a disease-modifying antirheumatic drug used for the treatment of inflammatory rheumatic diseases, especially systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) 330 . In lysosomes, hydroxychloroquine inhibits the degradation of cargo by increasing the pH and preventing the activity of lysosomal enzymes. This drug can inhibit nucleic acid sensors, such as cyclic GMP-AMP synthase, and prevents ligand binding to Toll-like receptor 7 (TLR7) and TLR9, thereby reducing the production of pro-inflammatory cytokines, including type I interferons 330 . In observational studies, hydroxychloroquine therapy was associated with a 72% decrease in the risk of cardiovascular events in patients with RA and a 68% reduction in thromboembolic events in patients with SLE 331, 332 . Hydroxychloroquine is currently being tested in two clinical trials in patients with coronary artery disease 252,253 ( TaBle 3) .

The cytokine IL-2 is essential for the growth and survival of regulatory T (T reg ) cells, which have a role in the control of inflammation. Low-dose IL-2 therapy has been trialled in patients with SLE, RA and psoriasis 333 . The principle of using low doses of IL-2 for the treatment of inflammatory diseases is based on the differential sensitivity of distinct immune cell subsets to IL-2. Among all T cell and natural killer cell subsets, T reg cells typically respond to the lowest concentrations of IL-2 owing to elevated surface expression of the IL-2 receptor subunitα (also known as CD25) and the high-affinity IL-2 receptor complex in this cell subset. Low-dose IL-2 therapy increases the number of T reg cells and the expression of functional markers, such as CD25, in patients with other inflammatory diseases 334, 335 . High-dose IL-2 therapy administered to patients with cancer is associated with adverse effects, but this severe toxicity is not justifiable in the setting of autoimmune diseases 333 . The ongoing phase II LILACS trial 254,336 is testing low-dose IL-2 therapy in patients with stable ischaemic heart disease and patients with acute coronary syndrome, with preliminary results showing effective expansion of T reg cells with the therapy. We look forward to the results of these and other exciting trials listed in TaBle 3 . The trial included 147 patients with stable atherosclerotic disease who were randomly assigned to receive a single dose of the anti-oxLDL antibody MLDL1278A, multiple doses of MLDL1278A or placebo. None of the MLDL1278A regimens had a significant effect on carotid plaque inflammation, possibly owing to the concomitant use of lipid-lowering medication, which might have masked the effect of passive vaccination with MLDL1278A 141 . This study also raises questions about the use of imaging as a surrogate end point for cardiovascular events. New PET-CT imaging tracers that can detect meaningful cardiovascular inflammation more accurately than FDG are needed 142 . An imaging technique developed in the past 4 years that is based on CT angiography showed that changes in the CT attenuation index of perivascular adipose tissue might be a marker of coronary perivascular inflammation associated with cardiovascular outcomes 143, 144 . Further improvements in the imaging of atherosclerosis will facilitate the development of valid surrogate end points of cardiovascular outcomes. Although cardiovascular surrogate end points are at present not sufficiently specific and, therefore, have not reached the benchmark of a clinical trial, developments in the field of machine learning could be used to combine multiple surrogate end points for a more accurate prediction of clinical outcomes 145, 146 .

Considering the above-mentioned successes in therapeutic targeting of the immune system in atherosclerosis, the number of ongoing trials in this setting is surprisingly low. One reason could be the high costs of clinical trials in CVD, which make this area less attractive for industry investments. Trials in CVD are event-driven rather than symptom-driven and, therefore, require high patient numbers and long follow-up. Therefore, identifying reliable surrogate markers of vascular inflammation is crucial to facilitate the design of small proof-of-principle trials, allowing rapid innovation and reduced risks. One crucial need is the early identification of patients who are likely to respond to a specific treatment and patients who would not benefit from the interruption of a specific inflammatory pathway. This concept is well exemplified by the CANTOS trial 32 , which demonstrated that patients with the larger reductions in hsCRP levels with canakinumab therapy derived the largest clinical benefit from the treatment. Patients with a decrease in hsCRP levels greater than the median percentage reduction had a 27% reduction in cardiovascular events compared with a reduction of only 5% in those patients with a decrease in hsCRP levels that was lower than the median 96 . Moreover, the fall in hsCRP levels has so far gone hand in hand with outcome benefits in the majority of clinical trials of anti-inflammatory therapies in CVD. In the future, new surrogate end points that are based on immunophenotyping and/or imaging could be used in clinical trials, provided that an association with cardiovascular outcomes is demonstrable.

Looking to the future, the secondary effects of anti-inflammatory therapies should be carefully considered. Canakinumab administration was associated with a major reduction in the incidence of lung cancer compared with placebo in the CANTOS trial 98 . By contrast, in the CIRT trial 135, 147 , methotrexate was linked to a small increase in the incidence of skin cancer compared with placebo, emphasizing the complexity of the effects of immunotherapy on CVD and cancer. Immunosuppression and chronic inflammation can both increase the risk of cancer 147 . Furthermore, preclinical studies have spotlighted the existence of an immune-mediated link between MI and breast cancer that can accelerate cancer progression 148 . An increasing number of studies have also shown that immune checkpoint inhibitor therapies might increase the risk of CVD in patients with cancer 36, 37 , whereas inhibition of adaptive immunity increases the risk of cancer through disruption of antitumour immunity 149 . Now that anti-inflammatory therapies in CVD are close to implementation in clinical practice, unravelling the complex immunological relationship between cancer and CVD is crucial.

Finally, the pathogenesis of CVD is multifactorial, and several types of coronary culprit lesions lead to the same clinical presentation and syndromes 17 . Different disease settings have distinct immune signatures, as illustrated by the different signatures in plaque erosion and rupture 150 , which calls for the identification of the disease setting in which a therapy will be most successful. Implementing deep immunophenotyping strategies can improve the selection of patients with the highest likelihood of benefiting from a specific therapy and facilitate rapid identification of responders and non-responders to therapy 151 . Immunophenotyping of patients with CVD is still in its infancy; however, a few of the currently available markers could guide patient selection, such as hsCRP and IL-6 levels in the plasma 96, 97, 152 . The discovery of CHIP as a novel risk factor of atherosclerosis will potentially enable further risk stratification of patients 153 . For example, a re-analysis of CANTOS data suggested that anti-inflammatory treatment might be more effective in patients carrying CHIP-associated gene variants 154 . Taken together, extensive immunophenotyping and immune-based risk stratification might facilitate patient selection and stratification and identification of treatment responders, allowing efficient design of clinical trials and realizing the potential of targeted immunomodulatory therapies for CVD.

In summary, the challenges in addressing the low-grade inflammation associated with CVD are manifold and encompass the need for careful risk-benefit assessment, the existence of several coronary syndromes with potentially different endotypes and pathogenesis, our current inability to identify responders to treatment early, and our reliance on 'hard' clinical end points in trial design owing to the limitations of our current imaging techniques. Further understanding of the immune signature of CVD together with the evolution of cardiovascular imaging technologies will accelerate the translation of therapies targeting inflammation from the preclinical to the clinical arena.

New targets for clinical translation Advances in our understanding of the pathogenesis of atherosclerosis have highlighted several potential cellular and molecular therapeutic targets. In this section, we focus on a selection of the most promising areas supported by the convergence of several lines of evidence from CVD and other diseases, and which are, therefore, closer to translation to patient therapies in the medium term (Fig. 3 ).

Targeting immunometabolic processes is a promising strategy for modulating inflammation and immunity. Atherosclerosis-associated changes in blood and bone marrow are regulated by immunometabolic events 155 . In mice, a Western diet and hyperglycaemia have been shown to induce epigenetic reprogramming of myeloid progenitors, which resulted in sustained monocyte and macrophage pro-inflammatory priming, thereby driving tissue inflammation and CVD [156] [157] [158] . These effects persisted even after restoring lipid and glucose levels to normal levels owing to the phenomenon of 'trained immunity' , whereby transcriptomic, epigenetic and metabolic rewiring of innate immune cells leads to an altered response towards a second challenge 159 .

Epigenetic regulation is of particular interest because of the potential for pharmacological inhibition. Histone deacetylases (HDACs) repress gene expression by removing open-chromatin acetylation marks. Broad HDAC inhibition in atherosclerotic mice showed mixed results [160] [161] [162] , whereas inhibition or genetic deletion of HDAC3 or HDAC9 reduced atherosclerosis in mice [163] [164] [165] . Variants in HDAC9 have been associated with abdominal aortic calcification and ischaemic stroke in genome-wide association studies in humans 166, 167 , highlighting the clinical potential of specific HDAC targeting in CVD.

Targeting metabolic rewiring is an alternative strategy because increased glucose metabolism in human and mouse haematopoietic stem and progenitor cells (HSPCs) dictates myeloid lineage commitment 168 . Glucose transporter 1 (GLUT1), a ubiquitously expres sed glucose transporter, is a well-recognized target in other inflammatory conditions 169 . GLUT1 deficiency in bone NaTure reviews | Cardiology R e v i e w s 0123456789();: marrow cells resulted in reduced HSPC proliferation, myelopoiesis and atherogenesis in mice 170 . However, further investigation of the effects of GLUT1 inhibition in humans is necessary, because patients with GLUT1 deficiency syndrome have neurological symptoms, such as epilepsy 171 .

The discovery of CHIP has led to the identification of new potential targets. The most commonly occurring variants associated with CHIP are loss-of-function variants in DNTM3A, ASXL1 and TET2 and gain-of-function variants in JAK2 (JAK2 V617F ), that all result in growth and survival advantages in the cells carrying the gene variant 172 . Mice with TET2 deficiency or carrying the Jak2 V617F variant showed accelerated atherogenesis 30, 153, 173, 174 . Both macrophages from Tet2-knockout mice and peripheral blood monocytes from patients with aortic valve stenosis carrying a DNTMA3 or TET2 variant produce high levels of IL-1β and show NLRP3 inflammasome priming 30, 153, 175 . NLRP3 inflammasome inhibition by administration of MCC950 prevented TET2-dependent atherosclerosis progression in mice in vivo 30, 153 . Similarly, clonal haematopoiesis driven by TET2 deficiency aggravated heart failure, cardiac dysfunction and obesity in mice, whereas NLRP3 inhibition with MCC950 protected against the development of heart failure and insulin sensitivity [176] [177] [178] . Activation of the absent in melanoma 2 (AIM2) inflammasome has been associated with Jak2 V617F -driven atherosclerosis in mice. In a mouse model of Jak2 V617F -driven atherosclerosis, deletion of the genes encoding for essential components that act downstream of the AIM2 inflammasome, such as caspase 1, caspase 11 and gasdermin D, induced a more stable plaque phenotype 179 (Box 4). Taken together, the findings of these studies highlight the potential of targeting CHIP-driven inflammation with the use of NLRP3 or AIM2 inflammasome inhibitors.

JAK2 inhibitors could represent an alternative strategy for targeting inflammation in atherogenesis. Ruxolitinib and fedratinib are FDA-approved drugs for the treatment of myeloproliferative neoplasms and are currently being tested for use in other inflammatory conditions, such as RA 180 . Both drugs were effective in reducing inflammation and atherosclerosis in mouse and rabbit models of atherosclerosis 174, 181 . Although treatment with the JAK1-JAK2 inhibitor ruxolitinib reduced atherosclerotic plaque size in mice with Jak2 V617F -dependent atherosclerosis 174, 179 , the treatment also increased necrotic core size and reduced cap thickness, resulting in an unstable plaque phenotype 179 . Therefore, a more specific JAK2 inhibitor, such as fedratinib, might be of interest in CVD.

Monocyte recruitment in atherosclerosis depends on the CCR2, CCR5 and CX3CR1 chemokine receptors 182 . Genetic deletion of Ccr2 or its ligand Ccl2 reduced bone marrow-derived monocytosis and atherosclerotic lesion size in mice 42, [183] [184] [185] . Similarly, mice with MI treated with a small interfering RNA (siRNA) targeting Ccr2 had decreased monocyte recruitment to the infarct area and reduced disease severity 186 . In humans, genetic predisposition to elevated plasma CCL2 levels is associated with an increased risk of stroke, MI and CAD, and increased CCL2 levels in the blood and atherosclerotic plaques correlate with a higher risk of stroke and with markers of plaque destabilization 187 . MLN1202, a CCR2-blocking antibody, reduced hsCRP levels in patients at risk of atherosclerotic CVD 188 . Pharmacological inhibition of CCR5 with the FDA-approved CCR5 antagonist maraviroc reduced atherosclerosis in Ldlr −/− mice 189, 190 . Interestingly, treatment with maraviroc also led to reduced atheroprogression in patients with HIV infection and high risk of CVD compared with baseline,

Toll-like receptors (TLRs) are a family of ten proteins in humans that recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), triggering an innate immune response 10 . Whereas the intracellular receptors TLR3 (reF. 337 ) and TLR7 (reF. 338 ) are involved in anti-atherogenic processes, the extracellular sensors TLR2 and TLR4 are thought to initiate the immune response in the arterial wall by recognizing modified lipoproteins in concert with scavenger receptors 15, 339 , leading to cell activation and induction of pro-inflammatory cytokines, such as IL-1β, while also priming the inflammasome, which regulates IL-1β production 340 . TLR2 and TLR4 are significantly upregulated in human atherosclerotic tissue 341 and on circulating monocytes from patients with acute coronary syndrome 342 , linking TLR levels to the risk of cardiovascular events 338, 343 . Although TLR4 induces the most powerful responses of any TLR in pathogen-related situations, mutations and/or deletions of Tlr4 in experimental models of atherosclerosis produced mixed results, with a varying degree of reduction or no effect on atherosclerotic lesion size 344 . By contrast, deletion of Tlr2 consistently reduced lipid deposition and macrophage content in atherosclerotic lesions in mice 345 . Moreover, inflammation in human atherosclerosis has been shown to be driven by TLR2 via the signalling adaptor MyD88 (reF. 217 ). Overall, this evidence strongly suggests that TLR2 is one of the most pro-atherogenic TLRs.

inflammasomes Inflammasomes are multimeric protein complexes that form in response to endogenous and exogenous danger signals, and promote pro-inflammatory cytokine production (including IL-1β and IL-18) and pyroptotic cell death 346 . The NLRP3 inflammasome is an important driver of lipid-driven vascular inflammation and atherosclerosis. Triggers for the activation of the NLRP3 inflammasome include potassium efflux, mitochondrial reactive oxygen species and cathepsin B 346 . All these triggers are likely to be present in the atheroma; however, a crucial driver of NLRP3 inflammasome activation in the arterial intima is cathepsin B activation downstream of cholesterol crystal, oxidized LDL and calcium phosphate crystal accumulation in phagocytic cells 347, 348 .

A crucial role for the absent in melanoma 2 (AIM2) inflammasome in atherosclerosis is emerging. In atherosclerotic mice, AIM2 inflammasome activation resulted in the production of IL-1β and IL-18 accompanied by an unstable plaque phenotype 349 . By contrast, Aim2 deletion or pharmacological inhibition with an AIM2-antagonizing synthetic oligo nucleotide increased plaque stability. Interestingly, AIM2 activation was also shown to be involved in atherosclerosis driven by clonal haematopoiesis 179, 350 . AIM2-dependent inflammasome formation depends on the detection of cytosolic double-stranded DNA 179 , possibly downstream of atherosclerosis-associated necrosis and apoptosis. AIM2 activation then leads to the release of cellular contents into the extracellular space, thereby driving inflammation.

Under normal conditions, the levels of NLRP3 or AIM2 inflammasome complexes in cells are minimal 351 , and the inflammasomes remain in an inactive state through ubiquitination 352 . Both, NLRP3 and AIM2 inflammasomes require an initial priming signal, which promotes the expression of proteins involved in inflammasome signalling in a nuclear factor-κB-dependent fashion and stimulates inflammasome deubiquitination 351, 352 . Subsequently, activation signals promote the assembly and activation of the inflammasome, enabling the proteolytic function of caspase 1 (reF. 346 ). In addition to the processing of IL-1 cytokines, inflammasome activation facilitates the cleavage of gasdermin D, thereby inducing pore formation in the plasma membrane and pyroptosis, which is critical for the release of IL-1β and IL-18 to further promote inflammation in atherosclerosis 353 . as assessed by intima-media thickness 191, 192 . However, given that circulating monocytes traffic into tissues during homeostasis, inflammation and inflammation resolution 47, 193 , the effect of targeting monocyte recruitment on these processes will need monitoring.

Macrophage polarization is orchestrated by key master regulators, including nuclear factor-κB, the STAT family, peroxisome proliferator-activated receptor-γ (PPARγ) and the interferon regulatory factor (IRF) family 194 . Reprogramming pro-inflammatory macrophage populations that drive vascular inflammation towards homeostatic pro-resolving phenotypes could reduce disease burden. Pioglitazone is an FDA-approved PPARγ agonist that induces a pro-resolving macrophage phenotype by reducing pro-inflammatory cytokine production and promoting monocyte differentiation into alternatively activated macrophages [195] [196] [197] . In mice with atherosclerosis, administration of pioglitazone reduced macrophage content and increased plaque stability 198, 199 . Clinical studies investigating the role of pioglitazone in patients with CVD and/or type 2 diabetes mellitus showed athero protective effects and a reduction of cardiovascular events with pioglitazone therapy [200] [201] [202] [203] , highlighting the therapeutic potential of this drug in CVD.

In mouse models of CVD, global or myeloid-specific IRF5 deficiency reduced atherosclerosis and improved plaque stability 204, 205 , and IRF5 inhibition with nanoparticles decreased myocardial infarct size 206 . The transcription factor IRF5 induces a pro-inflammatory phenotype in mouse and human macrophages 207 . Therefore, IRF5 is a promising therapeutic target in CVD. Inhibitors of IRF5 have proven to be therapeutically effective in mouse models of systemic lupus erythematosus 208, 209 .

Selective inhibition of the NLRP3 inflammasome with MCC950 reduced atherosclerosis in hypercholesterolaemic or diabetic mice 210, 211 . MCC950 has been tested in phase II trials in patients with RA, but the trials had to be discontinued owing to liver toxicity 212 . The interest in using NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory and neuroinflammatory diseases is increasing and these agents are being tested in clinical trials 213 . The NLRP3 inflammasome inhibitor OLT1177 has been assessed in phase I-II clinical trials in patients with osteoarthritis 214 , acute gout 213 or heart failure 215 and has shown high tolerability. OLT1177 is also currently being tested in a study in patients with ).

Alternative approaches to targeting the inflammasome in atherosclerosis include the prevention of inflammasome priming with the use of TLR inhibitors 217 , targeting the AIM2 inflammasome 179 and inhibition of caspase 1 (Box 4). The catalytic activity of caspase 1 is required to convert pro-IL-1β into its active form downstream of NLRP3 and AIM2. The caspase 1 inhibitor VX-765 reduces atherosclerosis in mice 218 . However, phase II trials of the caspase 1 inhibitors VX-740 and VX-765 in patients with psoriasis or epilepsy revealed drug-induced hepatotoxicity and further development was stopped 219 , highlighting the challenges presented by inhibition of inflammasomes.

Immune recognition of LDL and oxLDL moieties leads to the generation of autoantibodies and oxLDL-reactive T cells 14, 220 . Immunization with ApoB-derived antigens induces atheroprotective effects in mice and rabbits via diverse mechanisms including the induction of a humoral antibody response, T reg cell activation, suppression of CD4 + T cells and reduction of dendritic cell numbers in the plaque [221] [222] [223] . However, passive immunization with MLDL1278A, an anti-oxLDL antibody, added to lipid-lowering therapies did not reduce cardiovascular events in patients with stable atherosclerotic disease, as discussed above 141 . To improve the translation of ApoB-based immunization therapies from the preclinical to the clinical setting, Wolf and colleagues used in silico prediction methods to identify ApoB peptides that would bind to various major histocompatibility complex class II variants 81 . Using the in silico methods, the investigators identified 30 ApoB peptides that successfully induced a response in human T cells in vitro 81 .

Another approach to targeting adaptive immune cells is the direct targeting of atherogenic B cell subsets 224 . B cell depletion therapies are already in clinical use for the treatment of RA and multiple sclerosis, and studies in mice have shown that preferential B2 cell depletion with the use of an anti-CD20 antibody reduces atherosclerosis 225, 226 . A single dose of rituximab, a B cell-depleting anti-CD20 antibody, was safe and efficiently depleted B cells in patients with acute STEMI 227 . Antibodies for B cell depletion targeting CD19 (blinatumomab and inebilizumab), CD22 (inotuzumab ozogamicin) or B cell maturation antigen (belantamab mafodotin and AMG420) have been approved or are currently in clinical development for the treatment of multiple sclerosis and cancer. Other promising strategies targeting B cells include: impairment of B cell survival and proliferation (with atacicept, belimumab, blisibimod and ianalumab), modulation of B cell receptor signalling (with acalabrutinib, epratuzumab and ibrutinib), antibody neutralization (with omalizumab), and the modulation of B cell co-stimulation (with abatacept) 224, 228 .

Immune checkpoints are immune regulatory co-stimulatory molecules that provide stimulatory or inhibitory signals to adaptive and innate immune cells 229 . Immune checkpoints modulate the immune response in CVD 229 . In vivo studies in mice identified crucial co-stimulatory axes in atherosclerosis with the use of genetic deletion and agonistic and antagonist antibodies: activation of CD27-CD70, B and T lymphocyte attenuator (BTLA), CD200 receptor (CD200R)-CD200 and CD80/CD86-CTLA4 (cytotoxic T lymphocyte antigen 4) pathways or inhibition of CD40-CD40 ligand, OX40-OX40 ligand and CD30-CD30 ligand pathways might be beneficial therapeutic strategies in atherosclerosis [230] [231] [232] [233] [234] [235] [236] [237] . Multiple immune checkpoint NaTure reviews | Cardiology R e v i e w s 0123456789();: inhibitors and agonists targeting the above pathways are in clinical development for the treatment of cancer and RA 238, 239 . In preclinical models, specific inhibition of tumour necrosis factor receptor-associated factor 6 (TRAF6), downstream of the pro-inflammatory CD40 signalling pathway, with small-molecule inhibitors resulted in plaque stabilization without inducing adverse effects and sparing host defence 240 . Similarly, CD200R expression is restricted to the myeloid compartment, making the CD200-CD200R pathway amenable for selective targeting of the monocyte-macrophage axis locally and in the bone marrow in CVD 234 .

Long-term immunosuppression might disrupt cardiovascular homeostasis and host defence 241 . Local delivery of drugs has been used in the clinic in the vascular field for many years with the use of drug-eluting stents containing sirolimus or paclitaxel, both of which have anti-inflammatory properties 242 . Furthermore, microneedle injections of dexamethasone in the adventitia prevents restenosis in patients who have undergone percutaneous transluminal angioplasty 243 .

An alternative strategy for minimizing the systemic adverse effects of off-target cell activation with systemic immunosuppressive approaches and improving accessibility to the cell type of interest is the use of cell-targeted delivery approaches. Nanoparticles have a high engagement with myeloid cells and can be modified to target specific subsets with ligand-decorated nanomaterials 244 . Nanoparticles have been used to target macrophages in several trials in patients with CVD 245,246 . Flores and colleagues used PEGylated, single-wall carbon nanotubes to deliver a downstream inhibitor of the anti-phagocytic CD47 pathway to lesional macrophages in mice, which resulted in a reduced plaque burden without toxic effects 247 . Administration of macrophage-targeted nanoparticles carrying siRNA against Camk2g increased plaque stability in mice owing to improved efferocytosis, leading to rebalancing of the immune system in atherosclerosis 248 (Box 2). Nanoparticles decorated with collagen type IV accumulate in the atherosclerotic lesion shoulder and the use of these nanoparticles for the targeted delivery of IL-10 or the anti-inflammatory annexin A1 biomimetic Ac2-26 peptide stabilized atherosclerotic lesions in mice 249, 250 . TRAF6 inhibitors or pioglitazone delivered with nanoparticles was also effective in increasing plaque stability in atheroscler otic mice 198, 240 . These studies highlight the potential of modulating the immune system in CVD by specifically targeting atherosclerotic plaques to avoid toxic effects associated with systemic immunosuppression approaches.

Cardiovascular research lags behind oncology and rheumatology in recognizing the effects of chronic inflammation on CVD and translating inflammatory targets to human cardiovascular therapy. Although our understanding of the role of inflammation in atherosclerosis has improved substantially over the past two decades, the nuanced balance between pro-inflammatory and anti-inflammatory cells required for homeostasis remains elusive. To identify new therapeutic targets in atherosclerosis, we need to improve our interpretation of the determinants of this equilibrium. Single-cell biology approaches can accelerate clinical translation by facilitating the examination of immune signatures in patients with CVD. Identification of culprit cell types with the use of multiomics approaches could help identify the most suitable patient population for clinical trials and support target selection and informed decision-making in a clinical setting, moving towards personalized medicine. In addition, it is imperative to determine the window of opportunity for anti-inflammatory therapy in atherosclerosis, in which the benefits of immune system inhibition outweigh the systemic immunosuppressive effects. More targeted approaches using biologics or vaccination might allow specific targeting of atherosclerotic inflammation and thus minimize off-target effects. The development of mRNA vaccines has revolutionized the field of RNA-based therapeutics, extending the toolkit for vaccines against atherosclerosis and for previously 'undruggable' targets 251 . The association of CHIP with CVD risk exemplifies the importance of patient stratification beyond the use of traditional risk factors to define the patient population that will benefit from treatment. It is time to take inflammation seriously as a pathogenic driver of CVD and direct resources towards mechanistic and translational studies to find the cause of and a remedy for inflammation in this context. There has never been a more exciting time for research in cardiovascular inflammation.

Published online xx xx xxxx

Inflammation and atherosclerosis

ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines

ESC Guidelines for the diagnosis and management of chronic coronary syndromes

European Society of Cardiology: cardiovascular disease statistics 2019

The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina

Elevated levels of interleukin-6 in unstable angina

Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent

How the immune system shapes atherosclerosis: roles of innate and adaptive immunity

Pathogen recognition and innate immunity

The history of Toll-like receptors-redefining innate immunity

Monocyte-macrophages and T cells in atherosclerosis

Macrophages in the pathogenesis of atherosclerosis

APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans

T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein

CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer

Innate sensing of oxidation-specific epitopes in health and disease

From vulnerable plaque to vulnerable patient: a call for new definitions and risk www.nature.com/nrcardio s 0123456789();: assessment strategies: Part I

Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas

Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics

Single-cell analysis of fate-mapped macrophages reveals heterogeneity, including stemlike properties, during atherosclerosis progression and regression

Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry

Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models

Migratory and dancing macrophage subsets in atherosclerotic lesions

Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity

Single-cell immune landscape of human atherosclerotic plaques

Adventitial cell atlas of wt (wild type) and ApoE (apolipoprotein E)-deficient mice defined by single-cell RNA sequencing

Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis

Sleep modulates haematopoiesis and protects against atherosclerosis

Extramedullary hematopoiesis generates Ly-6C high monocytes that infiltrate atherosclerotic lesions

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

Targeting inflammation in atherosclerosis-from experimental insights to the clinic

Antiinflammatory therapy with canakinumab for atherosclerotic disease

Efficacy and safety of low-dose colchicine after myocardial infarction

Colchicine in patients with chronic coronary disease

Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis

Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque

Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis

How common is residual inflammatory risk?

Smooth muscle cell fate and plasticity in atherosclerosis

Role of smooth muscle cells in the initiation and early progression of atherosclerosis

Platelets in atherosclerosis

Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6Chi and Ly6Clo monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice

Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques

Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata

Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data

Identification of splenic reservoir monocytes and their deployment to inflammatory sites

Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression

Monocytes in atherosclerosis: subsets and functions

Modifiable cardiovascular risk, hematopoiesis, and innate immunity

Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression

Self-renewing resident arterial macrophages arise from embryonic CX3CR1+ precursors and circulating monocytes immediately after birth

Local proliferation dominates lesional macrophage accumulation in atherosclerosis

Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen

C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis

Ontogeny of arterial macrophages defines their functions in homeostasis and inflammation

Macrophage polarization

Revealing the origins of foam cells in atherosclerotic lesions

Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses

Inhibiting LXRα phosphorylation in hematopoietic cells reduces inflammation and attenuates atherosclerosis and obesity in mice

Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner

Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo

The role of efferocytosis in atherosclerosis

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques

Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice

CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice

Flt3 signaling-dependent dendritic cells protect against atherosclerosis

Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs

Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-α

Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein e-deficient mice

Neutrophils as regulators of cardiovascular inflammation

Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis

ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies

Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis

Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death

Extracellular DNA traps promote thrombosis

Atherosclerosis: neutrophil-derived cathelicidin protects from neointimal hyperplasia

T cell subsets and functions in atherosclerosis

Adaptive response of T and B cells in atherosclerosis

Heterogeneity of T cells in atherosclerosis defined by single-cell RNA-sequencing and cytometry by time of flight

Pathogenic autoimmunity in atherosclerosis evolves from initially protective apolipoprotein B100-reactive CD4 + T-regulatory cells

Cytotoxic and proinflammatory CD8 + T lymphocytes promote development of vulnerable atherosclerotic plaques in ApoE-deficient mice

The many faces of CD8 + T cells in atherosclerosis

Expansion of CD8+ T cells lacking the IL-6 receptor α chain in patients with coronary artery diseases (CAD)

Persistent accumulation of interferon-γ-producing CD8 + CD56 + T cells in blood from patients with coronary artery disease

Natural killer T cells in atherosclerosis

Co-accumulation of dendritic cells and natural killer T cells within ruptureprone regions in human atherosclerotic plaques

The role of B cells in atherosclerosis

B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions

B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10

Marginal zone B cells control the response of follicular helper T cells to a highcholesterol diet

Regulatory B cell-specific interleukin-10 is dispensable for atherosclerosis development in mice

Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production

Differential radiosensitivity among B cell subpopulations

Low-dose colchicine for secondary prevention of cardiovascular disease

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Management of acute pericarditis: treatment and follow-up

The British Society for Rheumatology guideline for the management of gout

Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments

Systematic review and metaanalysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

NLRP3 inflammasome and the IL-1 pathway in atherosclerosis

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis

Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice

The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin

Interleukin-1β in coronary arteries of patients with ischemic heart disease

Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA heart study

A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization

Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis

Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase α1 via a mitogen-activated protein kinase and c-Jun pathway

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a doubleblind, randomized, placebo-controlled phase 2 trial

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Inflammatory cytokines in atherosclerosis: current therapeutic approaches

Sinterleukin 23 levels are increased in carotid atherosclerosis possible role for the interleukin 23/interleukin 17 axis

Disruption of tumor necrosis factor-α gene diminishes the development of atherosclerosis in ApoE-deficient mice

Detection and localization of tumor necrosis factor in human atheroma

Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice

Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction

Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial

Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)

A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

The immunomodulatory effect of bone marrow stromal cells (BMSCs) on interleukin (IL)-23/IL-17-mediated ischemic stroke in mice

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Low-dose methotrexate for the prevention of atherosclerotic events

Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial

New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease

p38 Mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis

Losmapimod, a novel p38 mitogenactivated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity

Novel positron emission tomography tracers for imaging vascular inflammation

Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data

Detecting human coronary inflammation by imaging perivascular fat

Machine learning prediction in cardiovascular diseases: a meta-analysis

Artificial intelligence in hypertension: seeing through a glass darkly

Inflammation and cancer: triggers, mechanisms, and consequences

Myocardial infarction accelerates breast cancer via innate immune reprogramming

Human anti-tumor immunity: insights from immunotherapy clinical trials

Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study

Human monocyte heterogeneity as revealed by high-dimensional mass cytometry

Single-cell immune profiling in coronary artery disease: the role of state-of-the-art immunophenotyping with mass cytometry in the diagnosis of atherosclerosis

Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease

TET2-driven clonal hematopoiesis predicts enhanced response to canakinumab in the CANTOS trial: an exploratory analysis

Targeting immunometabolism as an anti-inflammatory strategy

Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis

Hypercholesterolemia-induced priming of hematopoietic stem and progenitor cells aggravates atherosclerosis

Western diet triggers NLRP3-dependent innate immune reprogramming

Trained immunity: a program of innate immune memory in health and disease

Valproate attenuates accelerated atherosclerosis in hyperglycemic ApoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis

Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis

Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptordeficient mice

Targeting macrophage histone deacetylase 3 stabilizes atherosclerotic lesions

Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development

Histone deacetylase 9 activates IKK to regulate atherosclerotic plaque vulnerability

HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype

Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke

Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification

Pharmacological inhibition of GLUT1 as a new immunotherapeutic approach after myocardial infarction

Disruption of Glut1 in hematopoietic stem cells prevents myelopoiesis and enhanced glucose flux in atheromatous plaques of ApoE −/− mice

Glut1 deficiency syndrome (Glut1DS): state of the art in 2020 and recommendations of the international Glut1DS study group

Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease

Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in JAK2V617F mice

Inhibition of JAK2 suppresses myelopoiesis and atherosclerosis in ApoE −/− mice. Cardiovasc

Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure

Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 INFLAMMASOME

Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction

TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity

The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit

Monocyte fate in atherosclerosis

Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes

Decreased lesion formation in CCR2 −/− mice reveals a role for chemokines in the initiation of atherosclerosis

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice

Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice

Monocyte-chemoattractant protein-1 levels in human atherosclerotic lesions associate with plaque vulnerability

Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region

Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice

Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice

Effects of therapy with maraviroc on the carotid intima media thickness in HIV-1/HCV co-infected patients

Maraviroc intensification modulates atherosclerotic progression in HIV-suppressed patients at high cardiovascular risk. A randomized, crossover pilot study

Monocyte recruitment during infection and inflammation

Transcriptional regulation of macrophage polarization: enabling diversity with identity

Pioglitazone: mechanism of action

Regulation of macrophage functions by PPAR-α, PPAR-γ, and LXRs in mice and men

PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties

Pioglitazone-incorporated nanoparticles prevent plaque destabilization and rupture by regulating monocyte/macrophage differentiation in ApoE −/− mice

Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. results from the PROactive

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Interferon regulatory factor 5 controls necrotic core formation in atherosclerotic lesions by impairing efferocytosis

Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe −/− mice

In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing

IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses

Inhibition of IRF5 hyperactivation protects from lupus onset and severity

Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease

Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis

NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein e-deficient micebrief report

Targeting the NLRP3 inflammasome in inflammatory diseases

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Phase 1B, randomized, doubleblinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 indibitor dapansutrile in subjects with NYHA II-III systolic heart failure

Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis

VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis

The potential for caspases in drug discovery

Vaccination strategies and immune modulation of atherosclerosis

CD8 + T cells mediate the atheroprotective effect of immunization with an ApoB-100 peptide

Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE −/− mice

Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice

B cells in atherosclerosis: mechanisms and potential clinical applications

B cell depletion reduces the development of atherosclerosis in mice

Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis

Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study

Impact of B-cell-targeted therapies on cardiovascular disease

Exploring immune checkpoints as potential therapeutic targets in atherosclerosis

Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis

Requirement for CD154 in the progression of atherosclerosis

Interference of the CD30-CD30L pathway reduces atherosclerosis development

CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice

CD200 limits monopoiesis and monocyte recruitment in atherosclerosis

Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice

Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice

B-and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition

Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis

Meta-analysis of corticosteroid treatment in acute myocardial infarction

Drug-eluting coronary stents: insights from preclinical and pathology studies

Adventitial drug delivery of dexamethasone to improve primary patency in the treatment of superficial femoral and popliteal artery disease: 12-month results from the DANCE clinical trial

Embracing nanomaterials' interactions with the innate immune system

Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration

A highly durable RNAi therapeutic inhibitor of PCSK9

Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis

SiRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice

Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis

RNA-targeted therapeutics for lipid disorders

Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis

Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain

In situ characterization of the foam cells in early human atherosclerotic lesions

Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies

Detection of activated T lymphocytes in the human atherosclerotic plaque

Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque

T lymphocytes in aortic and coronary intimas: their potential role in atherogenesis

Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells

Human vascular smooth muscle cells. Target for and source of tumor necrosis factor

Human interleukin 1 induces interleukin I gene expression in human vascular smooth muscle cells

Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β

Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (Op) and apolipoprotein E

Elevation of C-reactive protein in 'active' coronary artery disease

Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptordeficient mice

Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E

Autoantibody against oxidised LDL and progression of carotid atherosclerosis

The Wellcome Trust Case Control Consortium

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

Genomewide association analysis of coronary artery disease

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

Risk of cardiovascular mortality in patients with rheumatoid arthritis: a metaanalysis of observational studies

Risk of arterial thrombotic events in inflammatory bowel disease

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

Inflammation or atherogenesis

Inflammation, atherosclerosis, and coronary artery disease

Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody

Acute vascular events as a possibly related adverse event of immunotherapy: a singleinstitute retrospective study

The immune system in atherosclerosis

Development of apolipoprotein E-deficient mice

Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery

PCSK9 from basic science discoveries to clinical trials

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Of mice and not men: differences between mouse and human immunology

Conservation and divergence in the transcriptional programs of the human and mouse immune systems

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity

Naturalizing mouse models for immunology

Allometric scaling of wall shear stress from mice to humans: quantification using cine phase-contrast MRI and computational fluid dynamics

Mouse models of atherosclerosis and their suitability for the study of myocardial infarction

Plaque rupture in humans and mice

Human validation of genes associated with a murine atherosclerotic phenotype

Comparative transcriptomics in human and mouse

Translating mouse models: immune variation and efficacy testing

The porcine innate immune system: an update

The pig as a model for immunology research

Organs-on-chips: into the next decade

Of mice, dirty mice, and men: using mice to understand human immunology

The comparative immunology of wild and laboratory mice, Mus musculus domesticus

Hypercholesterolemia induces T cell expansion in humanized immune mice

MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis

CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis

Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species

kinase Cδ, and p38 mitogen-activated protein kinase (MAPK)

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

Deletion of macrophage LDL receptorrelated protein increases atherogenesis in the mouse

CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma

Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies

Integrin-associated protein (CD47) and its ligands

Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia

Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE −/− mice

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques

Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation

ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages

Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis

Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin

Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E −/− mice

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

Low-dose IL-2 therapy in autoimmune and rheumatic diseases

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

ATVB plenary lecture: Interleukin-2 therapy in cardiovascular disease: the potential to regulate innate and adaptive immunity

Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS)

Unexpected protective role for Toll-like receptor 3 in the arterial wall

Toll-like receptor 7 protects from atherosclerosis by constraining inflammatory macrophage activation

Toll-like receptors in atherosclerosis: a 'Pandora's box' of advances and controversies

Interleukin-1β and the autoinflammatory diseases

Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation

Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome

Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events

Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E

Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids

The inflammasomes

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

AIM2 stimulation impairs reendothelialization and promotes the development of atherosclerosis in mice

Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability

Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression

Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Athero-B-Cell), HEALTH-F2-2013-602222 (Athero-Flux), HEALTH.2012-1.2-1, contract number 305739 RiskyCAD, and (TAXINOMISIS) grant agreement

This article is dedicated to Prof. Attilio Maseri (1935-2021), who indicated the way for many of us to follow. 

All the authors contributed substantially to all aspects of the article.

The authors declare no competing interests.

Nature Reviews Cardiology thanks C.J. Binder, who co-reviewed with F. Porsch; A. Abbate; K. Ley; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version contains supplementary material available at https://doi.org/10.1038/s41569-021-00668-4.